...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gastroenterology and hepatology >The early on-treatment perihepatic lymph node response predicts sustained viral response of anti-hepatitis C virus therapy.
【24h】

The early on-treatment perihepatic lymph node response predicts sustained viral response of anti-hepatitis C virus therapy.

机译：早期治疗的肝周淋巴结反应预示着抗丙型肝炎病毒治疗的持续病毒反应。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND AIMS: In chronic hepatitis C, the change of perihepatic lymph nodal size after antiviral therapy could be a marker of virologic response. Whether the on-treatment nodal manifestations predict virologic responses is unknown. METHODS: Patients (n=88) with biopsy-proven chronic hepatitis C received standard doses of bi-therapy for 24 weeks; sequential changes of the perihepatic lymph nodes were evaluated prospectively by ultrasound. Pretreatment and on-treatment factors were analyzed and correlated with sustained virologic response, focusing on early on-treatment nodal changes (12 weeks). RESULTS: Perihepatic lymph nodes were prevalent in 75% of the patients; 72 patients (81.8%) achieved sustained viral response. Before treatment, no factor was significantly associated with the nodal prevalence or size. The pretreatment nodal width (mean 5.3 vs. 3.6 mm; P=0.023) and the on-treatment nodal manifestations including a reduction in nodal width at 12 weeks of antiviral treatment (median; 1.05 vs. 0 mm, P=0.029) and a reduction of nodal volume at the end of treatment (24 weeks; median 0.62 vs. -0.01 ml, P=0.015) were significantly correlated with the sustained virologic response. A reduction of nodal width greater than 2.5 mm at 12 weeks always predicts sustained virologic response (100 vs. 77%; P=0.019). CONCLUSION: Results confirm the high prevalence of perihepatic lymphadenopathy in patients with chronic hepatitis C. The use of the nodal width measurement in routine ultrasound follow-up may be a simpler early predictor of sustained virologic response during standard bi-therapy.
机译：背景与目的：在慢性丙型肝炎中，抗病毒治疗后肝周淋巴结大小的变化可能是病毒学应答的标志。尚不清楚治疗中的淋巴结转移是否能预测病毒学应答。方法：经活检证实的慢性丙型肝炎患者（n = 88）接受标准剂量的联合治疗，持续24周。超声检查肝周淋巴结的顺序变化。分析了治疗前和治疗中的因素，并将其与持续的病毒学应答相关联，重点在于治疗中早期的淋巴结改变（12周）。结果：75％的患者普遍存在肝周淋巴结肿大。 72位患者（81.8％）获得了持续的病毒反应。治疗前，没有任何因素与淋巴结的盛行或大小显着相关。治疗前的淋巴结宽度（平均5.3 vs. 3.6 mm; P = 0.023）和治疗中的淋巴结表现包括抗病毒治疗12周时淋巴结宽度的减少（中位数; 1.05 vs. 0 mm，P = 0.029）和治疗结束时（24周;中位数0.62对-0.01 ml，P = 0.015）淋巴结体积的减少与持续的病毒学应答显着相关。在第12周时，淋巴结宽度的减少大于2.5 mm总是可以预示持续的病毒学应答（100比77％; P = 0.019）。结论：结果证实了慢性丙型肝炎患者肝周淋巴结病的高患病率。在常规超声随访中使用节宽测量可能是标准双向治疗期间持续病毒学应答的更简单的早期预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号